← All Cyclacel Pharmaceuticals, INC filings

Cyclacel Pharmaceuticals, INC 8-K filings

CYCC
Cyclacel Pharmaceuticals, INC
8-K: Cyclacel Pharmaceuticals Faces Nasdaq Delisting Threat Due to Low Stockholders' Equity
Cyclacel Pharmaceuticals received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement of $2.5 million, reporting only $607,000 as of December 31, 2023.
CYCC
Cyclacel Pharmaceuticals, INC
8-K: Cyclacel Pharmaceuticals Reports 2023 Financial Results and Provides Clinical Program Update
Cyclacel Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a shift towards precision medicine strategies.
CYCC
Cyclacel Pharmaceuticals, INC
8-K: Cyclacel Pharmaceuticals Announces Departure of Chief Medical Officer and Appointment of Interim Replacement
Cyclacel Pharmaceuticals terminated its Chief Medical Officer, Mark H. Kirschbaum, M.D., and appointed board member Dr. Brian Schwartz as interim Chief Medical Officer, both effective January 25, 2024.
CYCC
Cyclacel Pharmaceuticals, INC
8-K: Cyclacel Pharmaceuticals Announces Quarterly Dividend on Preferred Stock
Cyclacel Pharmaceuticals has declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable on February 1, 2024.